Table 2 Patient demographics and bacteremia data AFFECT-1 Phase IIA trial.
Group | 100 mg Anakinra | 200 mg Anakinra | 300 mg Anakinra | ||||||
|---|---|---|---|---|---|---|---|---|---|
Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
Sex | F | M | M | M | M | F | M | F | M |
Age (years) | 50 | 68 | 60 | 67 | 66 | 66 | 55 | 64 | 57 |
BMI | 33.43 | 27.10 | 27.49 | 27.59 | 26.52 | 24.34 | 23.66 | 28.15 | 24.11 |
ECOG | Grade 1 | Grade 1 | Grade 0 | Grade 1 | Grade 1 | Grade 1 | Grade 0 | Grade 2 | Grade 0 |
MM stage (ISS) | Stage I | Stage II | Stage I | Stage II | Stage II | Stage I | Stage II | Stage III | Stage II |
Hospital stay (days) | 20 | 16 | 27 | 19 | 20 | 20 | 21 | 25 | 19 |
Days to engraftment | 14 | 18 | 19 | 15 | 16 | 13 | 20 | 14 | 14 |
First occurrence of fever | Day + 6 | Day + 9 | Day + 13 | NA | Day + 11 | Day + 8 | Day + 11 | Day + 6 | Day + 9 |
Bacteremia | Staphylococcus hominis (Day + 7, + 8, + 10) | Negative | Negative | Negative | Negative | Haemolytic streptococcus group C (Day + 8/ + 9) | Negative | Negative | Streptococcus mitis (Day + 9) |
CRBSI | Yes (Staphylococcus hominis) | No | No | No | No | No | No | No | No |
Use of antibiotics | Ceftazidime (Day + 5 to + 11) Teicoplanin (Day + 11 to + 16) | Ceftazidime (Day + 7 to + 12) | Ceftazidime (Day + 13 to + 18) Piperacillin/ Tazobactam (Day + 20 to + 23) | no | Ceftazidime Day + 11 to + 15) | Ceftazidime (Day + 8 to + 14) | Ceftazidime (Day + 11 to + 16) | Ceftazidime (Day + 6 to + 13) | Ceftazidime (Day + 9 to + 14) |
